Parallax Volatility Advisers, L.P. Mirati Therapeutics, Inc. Put Options Transaction History

Parallax Volatility Advisers, L.P.

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q4 2022 Feb 14, 2023	SELL	$41.27 - $98.62 $222,858 - $532,548	-5,400 Reduced 93.1%	400 $18,000
Q3 2022 Nov 14, 2022	BUY	$59.5 - $86.7 $345,100 - $502,860	5,800 New	5,800 $405,000
Q3 2021 Nov 15, 2021	BUY	$132.13 - $177.45 $3.03 Million - $4.06 Million	22,900 New	22,900 $4.05 Million
Q2 2020 Aug 14, 2020	SELL	$72.01 - $120.39 $295,241 - $493,599	-4,100 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$69.78 - $116.21 $20,934 - $34,863	-300 Reduced 6.82%	4,100 $315,000

Q4 2019 Feb 14, 2020	SELL	$70.76 - $128.86 $3.05 Million - $5.55 Million	-43,100 Reduced 90.74%	4,400 $568,000
Q2 2018 Aug 14, 2018	BUY	$26.05 - $52.4 $1.24 Million - $2.49 Million	47,500 New	47,500 $2.34 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Parallax Volatility Advisers, L.P., based on Form 13F filings with the SEC.

Stay updated on Parallax Volatility Advisers, L.P. with notifications on news.